Document is current
Any future updates will be listed below
-
Authors
Hilbers, Florentine S. https://orcid.org/0000-0002-6764-3102
Poncet, Coralie
Tryfonidis, Konstantinos
Viale, Giuseppe
Delaloge, Suzette https://orcid.org/0000-0003-2106-9165
Pierga, Jean-Yves https://orcid.org/0000-0002-2863-9995
Brain, Etienne G. C. https://orcid.org/0000-0003-0881-9371
Rubio, Isabel T.
Thompson, Alastair M.
Rutgers, Emiel J. T.
Piccart, Martine J.
van ’t Veer, Laura J. https://orcid.org/0000-0002-9838-8298
Cardoso, Fatima https://orcid.org/0000-0002-6692-2249
-
Funding
Funding for this research was provided by:
European Commission (FP6-LSHCCT- 2004-503426)
Breast Cancer Research Foundation
Novartis
Roche
Sanofi
Eli Lilly and Company
Susan G. Komen (SG05-0922-02)
KWF Kankerbestrijding
Deutsche Krebshilfe
- License Information
-
More Information
Article History
Received: 15 January 2024
Accepted: 9 July 2024
First Online: 2 November 2024
Competing interests
: LV reports personal fees and is stock-holder of Agendia NV. FC reports personal fees for consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime, none in relation with this work. GV reports personal fees for consultancy roles from Roche, AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, MSD Oncology, and Agilent, none in relation to this work. MP is a scientific board member for Oncolytics and reports personal fees for consultancy roles for: AstraZeneca, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Roche-Genentech, Seattle Genetics, Seagen, NBE Therapeutics, Frame Therapeutics; as well as institutional research grants from: AstraZeneca, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon, Gilead, none in relation with this work. KT is currently an employee of Merck. All other authors report no conflicts of interest.
